Evidence map›Paper›PMID 22251182›Full record

ArticleJournal of biopharmaceutical statistics2012

Average cost-effectiveness ratio with censored data.

Heejung Bang, Hongwei Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biopharmaceutical statistics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Median-based incremental cost-effectiveness ratios with censored data.Journal of biopharmaceutical statistics · 2016
    Article
  16. Observational
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Heejung BangDivision of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA. hbang@ucdavis.edu
Hongwei Zhao

Funding

A Unified Approach of Cost-Effectiveness AnalysisR01HL096575 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BANG, HEEJUNG · 2009 to 2011
$534k
NHLBI NIH HHS R01 HL096575NHLBI NIH HHS R01HL096575
6 · The paper itself

Abstract

In cost-effectiveness analysis, interest could lie foremost in the incremental cost-effectiveness ratio (ICER), which is the ratio of the incremental cost to the incremental benefit of two competing interventions. The average cost-effectiveness ratio (ACER) is the ratio of the cost to benefit of an intervention without reference to a comparator. A vast literature is available for statistical inference of the ICERs, but limited methods have been developed for the ACERs, particularly in the presence of censoring. Censoring is a common feature in prospective studies, and valid analyses should properly adjust for censoring in cost as well as in effectiveness. In this article, we propose statistical methods for constructing a confidence interval for the ACER from censored data. Different methods-Fieller, Taylor, bootstrap-are proposed, and through simulation studies and data analysis, we address the performance characteristics of these methods.

Indexed as

Models, StatisticalAlgorithmsComputer SimulationConfidence IntervalsCost-Benefit AnalysisHumansProspective Studies

Identifiers

PMID22251182
PMCPMC3307793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.